Generics BulletinGlenmark Pharmaceuticals Ltd. ’s rhinitis therapy Ryaltris (olopatadine HCl/mometasone furoate) has been approved in Australia, the first market where the fixed‐dose combination nasal spray is expecte
ScripGlenmark Pharmaceuticals Ltd. ’s rhinitis therapy Ryaltris (olopatadine HCl/mometasone furoate) has been approved in Australia, the first market where the fixed‐dose combination nasal spray is expecte
ScripThere are a lot of notable financial disclosures in BioNTech AG 's US Securities and Exchange Commission (SEC) filing indicating that the company may raise up to $100m in a future initial public offe
ScripMylan NV has a long history in the generic pharmaceutical market, maintaining its independence while plenty of other mid-sized specialty generic peers were absorbed into larger corporations. Now the